The continuous glucose monitor (CGM) played a part in significant reductions in HbA1c, the average glucose levels over a three-month period. It was also associated with a lower rate of hospitalization for people with type 2 diabetes on both multiple daily injection (MDI) and once-daily (basal) insulin therapy.
Abbott presented its findings from the study at the 59th Annual European Association for the Study of Diabetes (EASD) in Hamburg, Germany. The comparative study from the Swedish National Diabetes Register indicates CGM’s effectiveness in type 2 diabetes management.
Get the full story at our sister site, Drug Delivery Business News.